Marisa Toups
University of Texas Southwestern Medical Center
30 Papers
74 Citations
Marisa Toups is an academic researcher from University of Texas Southwestern Medical Center. The author has contributed to research in topics: Major depressive disorder & Medicine. The author has an hindex of 18, co-authored 30 publications. Previous affiliations of Marisa Toups include University of Pittsburgh & University of Texas at Austin.
Chat about Author
Papers
The Bidirectional Relationship of Depression and Inflammation: Double Trouble.
TL;DR: How the immune system regulates mood and the potential causes of the dysregulated inflammatory responses in depressed patients are described, and inflammation is likely a critical disease modifier, promoting susceptibility to depression.
1.3K
Establishing moderators and biosignatures of antidepressant response in clinical care (EMBARC): Rationale and design.
Madhukar H. Trivedi,Patrick J. McGrath,Maurizio Fava,Ramin V. Parsey,Benji T. Kurian,Mary L. Phillips,Maria A. Oquendo,Gerard E. Bruder,Diego A. Pizzagalli,Marisa Toups,Crystal Cooper,Phil Adams,Sarah Weyandt,David W. Morris,Bruce D. Grannemann,R. Todd Ogden,Randy L. Buckner,Melvin G. McInnis,Helena C. Kraemer,Eva Petkova,Thomas J. Carmody,Myrna M. Weissman +21 more
TL;DR: The study is designed to standardize assessment of biomarkers across multiple sites as well as institute replicable quality control methods, and to use advanced data analytic methods to integrate these markers.
269
Pro-Inflammatory Cytokines as Predictors of Antidepressant Effects of Exercise in Major Depressive Disorder
Chad D. Rethorst,Marisa Toups,Tracy L. Greer,Paul A. Nakonezny,Thomas J. Carmody,Bruce D. Grannemann,Ryan M. Huebinger,Robert Barber,Madhukar H. Trivedi +8 more
TL;DR: Results suggest that high TNF-α may differentially predict better outcomes with exercise treatment as opposed to antidepressant medications for which high T NF-α is linked to poor response, and confirm findings from studies of antidepressant medications that tie decreasing IL-1β to positive depression treatment outcomes.
198
Test–retest reliability of freesurfer measurements within and between sites: Effects of visual approval process
Zafer Iscan,Tony B. Jin,Alexandria Kendrick,Bryan C. Szeglin,Hanzhang Lu,Madhukar H. Trivedi,Maurizio Fava,Patrick J. McGrath,Myrna M. Weissman,Benji T. Kurian,Phillip Adams,Sarah Weyandt,Marisa Toups,Thomas J. Carmody,Melvin G. McInnis,Cristina Cusin,Crystal Cooper,Maria A. Oquendo,Ramin V. Parsey,Christine DeLorenzo,Christine DeLorenzo +20 more
TL;DR: To determine the effect of visual inspection on sample size required for studies of MRI‐derived cortical thickness, the number of subjects required to show group differences was calculated and significant differences observed across imaging sites, between visually approved/disapproved subjects, and across regions with different sizes suggest that these measures should be used with caution.
161
Effect of Sertraline on Depressive Symptoms in Patients With Chronic Kidney Disease Without Dialysis Dependence: The CAST Randomized Clinical Trial
S. Susan Hedayati,S. Susan Hedayati,L. Parker Gregg,L. Parker Gregg,Thomas J. Carmody,Nishank Jain,Nishank Jain,Marisa Toups,A. John Rush,Robert D. Toto,Madhukar H. Trivedi +10 more
TL;DR: Among patients with non–dialysis-dependent CKD and MDD, treatment with sertraline compared with placebo for 12 weeks did not significantly improve depressive symptoms, and these findings do not support the use of sERTraline to treat MDD in patients withNon– Dialysis- dependent CKD.